Accolade, Inc. (NASDAQ:ACCD) Short Interest Down 22.0% in February

Accolade, Inc. (NASDAQ:ACCD - Get Free Report) saw a significant decrease in short interest in February. As of February 28th, there was short interest totalling 1,560,000 shares, a decrease of 22.0% from the February 13th total of 2,000,000 shares. Based on an average trading volume of 2,060,000 shares, the short-interest ratio is presently 0.8 days. Approximately 2.1% of the company's shares are short sold.

Analyst Upgrades and Downgrades

A number of research firms recently weighed in on ACCD. Morgan Stanley lowered their price target on shares of Accolade from $6.00 to $5.00 and set an "equal weight" rating for the company in a report on Tuesday, December 17th. Raymond James reiterated a "market perform" rating on shares of Accolade in a research note on Thursday, January 9th. Piper Sandler downgraded shares of Accolade from a "strong-buy" rating to a "hold" rating in a research note on Wednesday, March 5th. William Blair downgraded shares of Accolade from a "strong-buy" rating to a "hold" rating in a research note on Wednesday, January 8th. Finally, Canaccord Genuity Group reiterated a "hold" rating on shares of Accolade in a research note on Wednesday, January 8th. Thirteen equities research analysts have rated the stock with a hold rating and one has issued a buy rating to the stock. According to data from MarketBeat, Accolade presently has an average rating of "Hold" and a consensus price target of $6.51.

Institutional Investors Weigh In On Accolade

A number of large investors have recently made changes to their positions in the company. Mission Creek Capital Partners Inc. purchased a new position in Accolade during the third quarter valued at approximately $38,000. Pallas Capital Advisors LLC purchased a new position in Accolade during the fourth quarter valued at approximately $38,000. Laird Norton Wetherby Trust Company LLC purchased a new position in Accolade during the fourth quarter valued at approximately $38,000. Boothbay Fund Management LLC purchased a new position in Accolade during the fourth quarter valued at approximately $43,000. Finally, Wealth Enhancement Advisory Services LLC purchased a new position in Accolade during the fourth quarter valued at approximately $48,000. Institutional investors and hedge funds own 84.99% of the company's stock.

Remove Ads

Accolade Trading Up 0.1 %

Shares of ACCD stock traded up $0.01 during trading hours on Thursday, reaching $7.00. 448,166 shares of the stock traded hands, compared to its average volume of 1,390,358. Accolade has a 1-year low of $3.08 and a 1-year high of $10.68. The business has a fifty day moving average price of $6.92 and a 200 day moving average price of $4.82. The company has a quick ratio of 2.63, a current ratio of 2.63 and a debt-to-equity ratio of 0.67. The firm has a market capitalization of $573.54 million, a PE ratio of -3.11 and a beta of 2.18.

Accolade (NASDAQ:ACCD - Get Free Report) last released its quarterly earnings results on Friday, January 10th. The company reported ($0.30) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.31) by $0.01. Accolade had a negative net margin of 40.36% and a negative return on equity of 20.74%. On average, equities research analysts forecast that Accolade will post -1.2 EPS for the current year.

Accolade Company Profile

Accolade, Inc, together with its subsidiaries, engages in the development and provision of personalized and technology-enabled solutions that help people to understand, navigate, and utilize the healthcare system and their workplace benefits in the United States. The company offers a platform with cloud-based intelligent technology and multimodal support from a team of advocates and clinicians, including registered nurses, physician medical directors, pharmacists, behavioral health specialists, women's health specialists, case management specialists, expert medical opinion providers, and primary care physicians.